KIDSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ORTHOPEDIATRICS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$22.03+0.08 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $529.79M
- P/E (TTM)
- –
- Dividend yield
- –
ORTHOPEDIATRICS CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trauma and deformity | $52.63M | $43.05M | – | $44.14M | $41.66M | $37.87M | – | $37.64M | $37.77M | $33.30M | – | $28.81M | 74.6% | +26.4% |
| Scoliosis | $16.88M | $15.44M | $17.60M | $16.26M | $18.52M | $13.66M | $15.63M | $15.64M | $13.68M | $10.20M | $9.66M | $10.30M | 23.9% | -8.9% |
| Sports medicine/other | $1.00M | $875.00K | $1.37M | $846.00K | $905.00K | $880.00K | $624.00K | $1.30M | $1.35M | $1.18M | $884.00K | $862.00K | 1.4% | +10.5% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $54.79M | $45.31M | $48.65M | $48.72M | $48.15M | $40.89M | $42.89M | $42.71M | $41.25M | $34.31M | $28.26M | $29.36M | 77.7% | +13.8% |
| International | $15.72M | $14.05M | $12.96M | $12.53M | $12.94M | $11.52M | $9.77M | $11.86M | $11.55M | $10.38M | $9.35M | $10.61M | 22.3% | +21.5% |
From the segment and revenue-disaggregation notes of Orthopediatrics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.